Ertapenem is a long-acting, 1β-methyl parenteral Group 1 carbapenem antibiotic that has a broad antibacterial spectrum and once-a-day dosing supported by clinical studies. Ertapenem is active against both Gram-positive and Gram-negative bacteria, including Enterobacteriaceae, Streptococcus pneumoniae and most species of anaerobic bacteria. Isolates from a variety of infections (intra-abdominal infections, skin/ soft-tissue infections, community-acquired pneumonia, pelvic infections and urinary tract infections) are inhibited by ertapenem. It has restricted activity against nosocomial pathogens such as Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant staphylococci and enterococci. Ertapenem has potent activity against the majority of anaerobic isolates from intra-abdominal infections, and against most of the aerobes isolated from these infections, with the exceptions of the nosocomial pathogens mentioned above. MIC 90 s for most species of Enterobacteriaceae were <1 mg/L, significantly lower than those of imipenem. MIC 90 s for most Bacteroides fragilis group isolates ranged from 1 to 4 mg/L, and MIC 90 s were species specific for Clostridium, ranging from 0.06 mg/L for Clostridium perfringens to 4 mg/L for Clostridium clostridioforme. Ertapenem was equivalent to or better than piperacillin-tazobactam in activity against most anaerobic species isolated from these infections, and was more potent than piperacillin-tazobactam and ceftriaxone against the most common skin pathogens (e.g. methicillin-susceptible Staphylococcus aureus). Ertapenem was highly active against most of the pathogens isolated from patients with communityacquired pneumonia, except for isolates of methicillin-resistant S. aureus (which are infrequent causes of community-acquired infection); these isolates were also resistant to ceftriaxone. Resistance to ertapenem is most commonly attributable to a variety of mechanisms including alterations in penicillin-binding proteins in Gram-positive organisms, and combinations of potent metallo-β-lactamase enzymes, porin protein defects and efflux pumps in Gram-negative organisms.
Introduction
Carbapenems are β-lactam antibiotics that have a carbon instead of a sulphone in the 4-position of the thyazolidinic moiety of the β-lactam ring. 1 Imipenem, a Group 2 carbapenem, 2 had potent activity against a broad spectrum of bacteria, but was susceptible to hydrolysis by the renal dehydropeptidase enzyme (DHP-I), and therefore was combined with a potent inhibitor of DHP-I, cilastatin. 3 Ertapenem is a long-acting, 1β-methyl parenteral Group 1 carbapenem 2 that has a broad antibacterial spectrum. 4 Pharmacokinetic studies have indicated that serum half-lives of ertapenem approached those of ceftriaxone. Protein binding levels were also equivalent to those of ceftriaxone. Owing to the presence of the 1β-methyl substituent, hydrolysis by DHP-I was one-quarter that of imipenem. 5 Clinical and pharmacokinetic studies support once-a-day dosing for ertapenem. [6] [7] [8] 
Spectrum of activity
Ertapenem is active against both Gram-positive and Gram-negative bacteria, including Enterobacteriaceae, Streptococcus pneumoniae and most species of anaerobic bacteria. Isolates from a variety of infections [intra-abdominal infections, skin/soft-tissue infections, community-acquired pneumonia, pelvic infections and urinary tract infections (UTIs)] are inhibited by ertapenem. It has restricted activity against nosocomial pathogens such as Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant staphylococci and enterococci. 4 Ertapenem MICs for Gram-negative bacteria are generally lower than those of imipenem, whereas ertapenem MICs for Gram-positive bacteria are generally higher than those of imipenem. These differences, however, are probably not of great clinical significance, except with regard to P. aeruginosa and Acinetobacter. The activity of ertapenem against P. aeruginosa and Acinetobacter species is lower than that of other carbapenems, such as imipenem and meropenem. 9, 10 There are also differences in activity against enterococci (ertapenem has higher MICs) and Proteeae (imipenem has higher MICs). Like other β-lactam agents, ertapenem is not indicated for use against atypical organisms.
Carbapenems are generally stable to almost all clinically relevant β-lactamases, except for the uncommon Class B β-lactamases 1 Resistance to carbapenems and activity against isolates resistant to other antimicrobials is reviewed in more detail below.
Activity of ertapenem in relation to pharmacokinetics
The mean plasma concentration profile of total ertapenem was measured in 68 healthy adult volunteers following a single 1 g intravenous infusion, and related to the MIC 90 values for common clinical bacterial pathogens from a variety of infections. 11 The mean total plasma concentration and the concentration of free drug were greater than the MIC 90 values for 24 h and 8 h, respectively, for the following organisms: Enterobacteriaceae, streptococci, methicillin-susceptible Staphylococcus aureus (MSSA), Haemophilus influenzae, Moraxella catarrhalis, B. fragilis group isolates and all other anaerobes tested. Activity against enterococci and P. aeruginosa was limited, although when these organisms were part of polymicrobial infections in clinical trials, ertapenem was as effective as piperacillin-tazobactam (activity against enterococci in intra-abdominal infections does not seem to be an important factor in cure rates). Several factors that may be important in determining the optimal dosing regimen of an antibiotic (including MIC, bactericidal activity and post-antibiotic effect) were investigated in a study of ertapenem, imipenem and ceftriaxone. Also, a sub-MIC effect (SME), which mimics the clinical situation, in which the bacteria are exposed to supra-inhibitory concentrations followed by sub-inhibitory concentrations, was studied. Ertapenem had a post-antibiotic SME of 5-7 h against S. pneumoniae, H. influenzae and Enterobacter cloacae, and shorter effects against S. aureus and Escherichia coli. Ertapenem, imipenem and ceftriaxone exhibited a post-antibiotic effect against the Gram-positive strains tested but not against the Gram-negative strains. 6
Activity of ertapenem against clinical isolates from a variety of infections
MIC 90 s of ertapenem, piperacillin-tazobactam and ceftriaxone for various bacteria determined in several large clinical studies as well as from studies of isolates from particular entities are presented in Tables 1-3 ; the most salient points are discussed below. It is worthwhile to note that the susceptible breakpoint for ertapenem is defined as 1 mg/L for many organisms including Gram-positive cocci. The MIC 90 for some species (e.g. penicillin-resistant S. pneumoniae) varies slightly between studies (between 1 and 2 mg/L). If the MIC 90 is at or below the breakpoint (i.e. in the first case) the agent will be considered active. In the latter case (i.e. MIC 90 ≥ 2× the breakpoint), the agent will not be considered active. Since most susceptibility determining techniques (agar and microbroth dilution) are considered to have an allowable 2-fold dilution error, some of this interpretative determination will not be significant.
A large study of nearly 3500 isolates from 12 centres in Europe and Australia found the MIC 90 s of ertapenem for all species of Enterobacteriaceae to be <1 mg/L. For most species of Enterobacteriaceae, ertapenem MIC 90 s were significantly lower than those of imipenem. Three strains of Enterobacter aerogenes (of 1611 Enterobacteriaceae tested) were resistant to ≥16 mg/L (the three strains were from Greece, Belgium and the UK), and the authors commented that resistance in these organisms is often due to a combination of hyperproduction of an AmpC β-lactamase or an extended-spectrum β-lactamase (ESBL) and loss of a porin; however, the cause of resistance in these isolates was not determined. Most Enterococcus faecalis isolates had low-level resistance to ertapenem, with MIC 90 s of 16 mg/L; imipenem was more active against these isolates (MIC 90 4 mg/L). Although ertapenem was slightly less active than imipenem against streptococci and methicillin-susceptible staphylococci, this was not considered clinically significant as its MIC 90 remained ≤0.5 mg/L. 10 A large survey of 5558 isolates from 11 North American centres also found that ertapenem was active (more active than imipenem) against Enterobacteriaceae; MIC 90 s ranged from ≤0.008 mg/L for Salmonella and Shigella spp. to 0.5 mg/L for Enterobacter spp. Oxacillin-resistant staphylococci and enterococci were resistant to both carbapenems, and Acinetobacter and Pseudomonas species were resistant to ertapenem. 9 Another study of 545 bacterial isolates also found that ertapenem was more active than imipenem against Enterobacteriaceae (from as little as three times greater activity against Citrobacter diversus to 12-90 times greater activity against members of the tribe Proteeae). However, imipenem was more active against Pseudomonas and Acinetobacter species. MIC 90 s of ertapenem for isolates of Enterococcus, MRSA and Staphylococcus haemolyticus were >16 mg/L. 14 As part of a larger study to test resistant strains, strains without known resistance mechanisms were also tested. 13 
Activity of ertapenem against isolates from specific clinical entities

Intra-abdominal infections
Intra-abdominal infections include a variety of conditions including peritonitis, diverticulitis, appendicitis, intra-abdominal abscess and intrahepatic infection. 29 The most serious infections almost always involve a mixture of aerobic and anaerobic intestinal flora. A detailed study of the bacteriology of perforated and gangrenous appendicitis revealed an average of 10.2 different organisms per specimen, totalling 223 anaerobes and 82 aerobic or facultative bacteria. 30 All of the specimens received had a complex flora. In this study, 21 different genera and more than 40 species were encountered. B. fragilis group and E. coli were isolated from almost all specimens. In vitro activity of ertapenem ii15 In another study of the in vitro activities of aerobes from patients with complicated intra-abdominal infections, 74.6% of isolates were susceptible to ≤2 mg/L ertapenem and 21.9% of isolates were resistant to ≥8 mg/L (these included enterococci, MRSA, A. baumannii and P. aeruginosa). 16 Ertapenem was more active than piperacillintazobactam and ceftriaxone against Enterobacteriaceae, the most common aerobic pathogens.
Our laboratory tested a total of 244 strains of anaerobic bacteria isolated from intra-abdominal infections. 31 Summary. Ertapenem had potent activity against the majority of anaerobic isolates from intra-abdominal infections, and against most of the aerobes isolated from these infections, with the exceptions of those organisms known to be resistant to ertapenem (i.e. enterococci, MRSA, Acinetobacter and P. aeruginosa). P. aeruginosa is recovered relatively infrequently from these infections, and whereas enterococci are more commonly isolated, their role in pathogenesis is questionable. P. aeruginosa, Enterococcus and Acinetobacter are more commonly found in nosocomial infections.
Skin and soft-tissue infections
Complicated skin and skin-structure infections are more prevalent in patients with diabetes mellitus, cellulitis and post-traumatic or postsurgical skin or soft-tissue infection. Cutaneous and other soft-tissue infections may account for ∼2% of all visits to the emergency room and are often observed in injection-drug users. 32 The primary pathogens are S. aureus and β-haemolytic streptococci, although a number of Gram-positive and Gram-negative aerobic and anaerobic bacteria may be involved. 23, 33 Commonly encountered anaerobes were Fusobacterium nucleatum, pigmented Prevotella species, Peptostreptococcus micros, Actinomyces odontolyticus and Veillonella species. Among patients who had no history of intravenous drug use, S. aureus was again the most common isolate, followed by coagulase-negative staphylococci, 'S. milleri' (19%) and Streptococcus pyogenes (16%). The main groups of anaerobes were Peptostreptococcus species, Bacteroides species and Gram-positive bacilli. The broad range of organisms found in complicated skin and skin-structure infections demands that empirical treatment cover a broad spectrum of aerobic and anaerobic bacteria.
Goldstein et al. 23 studied anaerobic isolates from patients with complicated skin and skin-structure infections that required surgical intervention. Two hundred and thirty-two anaerobes were isolated from these patients, including Gram-negative species (Bacteroides, Prevotella, Porphyromonas, Fusobacterium, Bilophila, Dialister pneumosintes and Veillonella species), Gram-positive cocci and other Gram-positive bacilli. MIC 90 s for the organisms tested are summarized in Tables 1-3 . Briefly, 137 of 141 anaerobes tested (97.2%) were susceptible to ertapenem. Four Peptostreptococcus isolates were either intermediate or resistant to ertapenem.
In isolates from patients from the same clinical trial, 518 aerobic and facultative bacterial pathogens were tested. 18 The ertapenem MIC was ≤2 mg/L for 80.9% of the isolates and ≥8 mg/L for 16.2% of the isolates. MIC 90 s for the major groups isolated were: MSSA 0.25 mg/L, S. pyogenes 0.03 mg/L and E. coli ≤0.016 mg/L. Resistant isolates included enterococci, MRSA, P. aeruginosa and other nonfermentative Gram-negative bacilli.
Summary. Ertapenem was very active against many aerobic, facultative and anaerobic pathogens found in complicated skin and soft-tissue infections. Ertapenem was equivalent to or better than piperacillin-tazobactam in activity against most anaerobic species isolated from these infections and was more potent than piperacillintazobactam and ceftriaxone against Enterobacteriaceae and MSSA, which together comprise the most common skin pathogens.
Bite-wound infections
The aerobic and anaerobic flora of the biting animal or human is important in the pathogenesis of serious bite-wound infections. 15 Ninety-eight per cent of the isolates studied were inhibited by ertapenem at ≤4 mg/L. Ertapenem was only moderately active against Corynebacterium spp. (MIC 90 4 mg/L), Staphylococcus epidermidis (MIC 90 4 mg/L) and Enterococcus species (MIC 90 8 mg/L). Eubacterium species isolated from these infections were more susceptible to ertapenem and to piperacillin-tazobactam than those isolated from other types of infection. Campylobacter species were the most resistant: five strains of Campylobacter (four of five strains of Campylobacter gracilis and one of three strains of Campylobacter rectus) required ertapenem ≥16 mg/L for inhibition.
Summary. Ertapenem was very active against all the isolates found in bite wounds (comprising ∼30 different species), except for the few species noted above. Piperacillin-tazobactam had better activity against Enterococcus than either ertapenem or ceftriaxone, and none of the agents were active against the Bacteroides ureolyticus/ Campylobacter strains tested.
Pelvic infections
Pelvic infections are often polymicrobial, with pathogens representing the normal vaginal flora. In a study of acute pelvic infections, aerobic and anaerobic isolates (814 total) from centres in the USA, Latin America, Europe, Russia and South Africa were collected and the antimicrobial activity of ertapenem and comparator agents evaluated. 17 E. coli was the most common aerobe, and Peptostreptococcus was the most common anaerobe, followed by Bacteroides. All iso-lates of Enterobacteriaceae were susceptible to ertapenem (MIC 90 s ≤ 0.125 mg/L). As expected, strains of P. aeruginosa, A. baumannii and enterococci were resistant to ertapenem. MIC 90 s for the most common anaerobic isolates were, respectively: B. fragilis 1 mg/L, Porphyromonas spp. <0.06 mg/L, Prevotella bivia 0.25 mg/L and Peptostreptococcus spp. 1 mg/L. Although the enterococci that were isolated from patients were not susceptible to ertapenem, in the clinical trial corresponding to this in vitro study all those patients who were treated with ertapenem were cured, confirming the lack of virulence of enterococci in these infections.
Summary. In this study, ertapenem was highly active against many of the pathogens recovered from patients with acute pelvic infections. Ertapenem was more active than piperacillin-tazobactam and ceftriaxone against Enterobacteriaceae. Ertapenem was much more active than ceftriaxone against isolates of the B. fragilis group, and either equivalent to or more active than ceftriaxone or piperacillintazobactam against most other anaerobic species found in these infections.
Pneumonia
S. pneumoniae is the most common cause of community-acquired pneumonia in adults and children, and is associated with the greatest morbidity. It is also the organism most likely to be resistant to antimicrobial agents. Other common respiratory tract pathogens are M. catarrhalis and H. influenzae; a number of other genera may be involved in these infections.
The in vitro activity of ertapenem against a total of 381 respiratory bacterial pathogens isolated from patients with community-acquired pneumonia and exacerbation of chronic bronchitis was determined. The activity of ertapenem was compared with a challenge set of 102 clinical isolates of S. pneumoniae, many of which had been characterized previously with respect to specific resistance mechanisms. 20 MIC 90 s of ertapenem, imipenem and meropenem were 2, 0.5 and 1 mg/L, respectively. Owing to the higher breakpoint of ertapenem for pneumococci (justified by improved pharmacokinetic characteristics), this translated into 84.3%, 50% and 56.9% susceptibility to the three agents, respectively. Whereas ertapenem MIC 90 s increased according to penicillin susceptibility (0.03, 0.5 and 2 mg/L for penicillin-susceptible, -intermediate and -resistant strains, respectively), the 33 penicillin-intermediate isolates were inhibited by ertapenem at ≤1 mg/L and 68% of fully penicillin-resistant organisms were inhibited at this concentration. In general, pneumococci that were resistant to β-lactams or carbapenems also had higher resistance rates to ertapenem, as would be expected. Resistance to clindamycin or tetracycline did not correlate with ertapenem resistance. Erythromycin-resistant pneumococci were somewhat less susceptible to ertapenem. Approximately 77% of quinolone-susceptible isolates were susceptible to ertapenem but, oddly, 100% of quinoloneintermediate or -resistant isolates were susceptible to ertapenem. The authors did not comment on possible explanations for these data.
In a more-detailed study of S. pneumoniae, the activity of ertapenem was determined by the microdilution and by the time-kill methods. 21 For all 285 strains tested, ertapenem MIC 90 s for penicillinsusceptible (n = 125), -intermediate (n = 74) and -resistant (n = 86) organisms were 0.03, 0.5 and 1.0 mg/L, respectively. In comparison, imipenem and meropenem MIC 90 s for the same organism groups were <0.008, 0.25 and 0.25 mg/L, and 0.016, 0.5 and 1 mg/L, respectively. Sixty-four strains that were quinolone resistant were further subdivided by penicillin resistance; the only difference found was that imipenem MICs for penicillin-resistant strains were slightly lower than those for quinolone-resistant isolates (MIC 90 0.25 mg/L versus 1 mg/L). Killing activity was tested at the MIC and at 2 × MIC over a 24 h period. 21 At 2 × MIC, the killing rate was 90%, 99% and 99.9% at 6, 12 and 24 h, respectively. Ertapenem was bactericidal at 24 h at 2 × MIC. In comparison, at the MIC, imipenem had more bactericidal activity at 24 h than either ertapenem or meropenem (99% reduction in 11/12 strains, 99.9% reduction in 7/12 strains). However, at 2 × MIC or higher, the killing kinetics of the three carbapenems at 24 h were similar.
Summary. Ertapenem was highly active against most of the pathogens isolated from patients with community-acquired pneumonia or bacterial exacerbation of chronic bronchitis, except for isolates of MRSA (which are infrequent causes of community-acquired infection); these isolates were also resistant to ceftriaxone. Isolates that were fully resistant to penicillin also had higher ertapenem MICs, although most of these isolates were still in the susceptible range.
Urinary tract infections
UTIs are considered to be the most common bacterial infection, accounting for 7 million doctor visits per year. 34 Uncomplicated UTIs typically occur in healthy young women; the current treatment trend is for empirical, short-course, patient-initiated therapy. 35 Complicated UTIs (which may include pyelonephritis or may be associated with obstruction, foreign bodies or urological abnormalities) or UTIs in men require more intensive therapy, which typically includes a broad-spectrum parenteral agent followed by an oral agent. In a study evaluating the efficacy of ertapenem (versus ceftriaxone) followed by an oral agent for use in complicated UTIs, the most common pathogens isolated were E. coli (69%) and K. pneumoniae (12-13%). 7 Bacterial recurrence rates were 7.6% and 8.3% for patients treated with ertapenem and ceftriaxone, respectively; the recurrent pathogens had not developed resistance to either agent.
Summary.
No MICs for individual isolates were reported in this study but the authors concluded that, on the basis of in vitro susceptibility data, the high urine concentrations of ertapenem and the results of clinical efficacy studies, ertapenem would appear to be an appropriate choice for the initial empirical treatment of most patients with complicated UTIs.
Activity of ertapenem against anaerobic bacteria
A multicentre survey compared the susceptibility of 2673 isolates of B. fragilis group species between 1997 and 2000, and found no significant change in the resistance rate during this time period (0.8-0.9%). 36 The resistance rate was somewhat dependent on species; for example, the overall resistance rate of ertapenem was <1% for B. fragilis group isolates in 2000, but 2.8% of Bacteroides distasonis strains were resistant. The average resistance rate for the ii18 B. fragilis group for this 4 year period was 1% (1.2% for the species B. fragilis). In another study of B. fragilis group isolates, 309 strains from a variety of clinical sources were studied. The ertapenem MIC 90 for all strains tested was 2 mg/L. There was little variance in MIC 90 s among the various species (all 1-2 mg/L). 27 Aldridge 26 reported on the anti-anaerobic activity of ertapenem on 556 isolates from a variety of anatomical sites. The overall MIC 90 was 1 mg/L and at ≤4 mg/L, 99.1% of all anaerobes were inhibited. The highest MICs were seen for the members of the B. fragilis group, with some strains of B. fragilis having MICs of 32 mg/L. All other species tested (Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus) had MIC 90 s of ≤0.25 mg/L.
A report comparing the activity of ertapenem, imipenem and meropenem against 363 anaerobic isolates found no carbapenemresistant strains. 24 The MIC 90 of ertapenem was 4-fold higher than that of imipenem for strains of B. fragilis (but still 2.0 mg/L). Of the B. fragilis group species other than B. fragilis, Bacteroides thetaiotaomicron was the most resistant (60% of isolates had MICs > 1 mg/L compared with 16% of the other species). Among the Clostridium species, C. difficile was the most resistant (ertapenem MIC 90 8.0 mg/L versus imipenem and meropenem MIC 90 s of 4 and 2 mg/L, respectively). 24 A number of less-commonly encountered anaerobic pathogens representing 11 genera and 52 species was studied by Goldstein et al. 37 These included Actinomyces species, Anaerobiospirillum, a variety of less common Bacteroides species, Clostridium species, Fusobacterium species, Porphyromonas, Prevotella and Veillonella. Ertapenem was active against the majority of anaerobes tested with very low MIC 90 s (0.06-<0.015 mg/L) for certain species (some Fusobacterium and Porphyromonas species, Campylobacter gracilis and Anaerobiospirillum). Nine different Clostridium species showed species variation in their susceptibilities to ertapenem, with MIC 90 s ranging from <0.015 mg/L (Clostridium cadaveris) to 8 mg/L (C. difficile). Lactobacillus strains were the most resistant to ertapenem (and also to imipenem and meropenem), with MIC 90 s of >16 mg/L.
Time-kill studies were performed on 10 isolates of different species. At 2 × MIC, ertapenem was bactericidal (99.9% killing) for 9/10 strains after 48 h; 90% killing of all 10 strains was seen after 24 h. One strain of C. difficile was not killed by ertapenem or imipenem but was killed by meropenem at 2 × MIC after 48 h. In this study, MICs were determined for 431 recent clinical anaerobic isolates. MIC 90 s for the B. fragilis group were 1 or 2 mg/L, and 0.125-0.5 mg/L for Prevotella species. C. difficile was the most resistant species with an MIC 90 of 8 mg/L. 28
Summary. Ertapenem had excellent activity and good kill kinetics against a wide variety of anaerobic species, with the exception of C. difficile (and, in one study, B. wadsworthia). In comparison, ceftriaxone is much less active against many species, particularly isolates of the B. fragilis group. Ertapenem also inhibited the growth of most less-frequently identified anaerobic pathogens.
Resistance to ertapenem and other carbapenems
The best described mechanisms of carbapenem resistance include changes in outer membrane proteins, multi-drug efflux pumps and potent metalloenzymes that hydrolyse carbapenems. This is best described in Pseudomonas species, in which both porins (loss of OprD) 38,39 and efflux pumps have been implicated in carbapenem resistance. Combinations of these mechanisms may also play a role in resistance. 40 Mutants with changes in porin proteins may in fact be selected by the antimicrobial agent; consumption of imipenem has been correlated with β-lactam resistance in Pseudomonas. 41 The mechanisms of ertapenem passage into the cell or active efflux of ertapenem out of the cell have not yet been described.
The role of β-lactamases in carbapenem resistance
Resistance to β-lactams may be mediated by the hydrolysis of the antibiotic by a β-lactamase enzyme. These enzymes constitute a heterogeneous group with confusing nomenclature. Two main classification schemes are used. One scheme, introduced by Ambler in 1980, 42 describes enzyme classes A-D, based on their amino acid sequence. Classes A, C and D are composed of evolutionarily distinct groups of serine enzymes, and class B is composed of the zincdependent (EDTA-inhibited) enzymes. The second scheme is a functional classification scheme proposed by Bush and colleagues. 43, 44 In this scheme, β-lactamases fall into four major groups and correspond roughly to particular Ambler groups. These include: (i) Group 1/Ambler Class C: chromosomal β-lactamase enzymes (not inhibited by clavulanic acid) that generally do not hydrolyse carbapenems.
(ii) Group 2/Ambler Classes A and D: includes many different enzyme types including penicillinases, cephalosporinases, oxacillinases and carbapenemases (with active site serine, inhibited by clavulanic acid). They include the broad-spectrum β-lactamases from Gram-negative bacteria and extended spectrum β-lactamases (ESBLs) (which confer resistance to oxyimino-cephalosporins and monobactams). Most ESBLs and broad-spectrum β-lactamases are Class A enzymes. (iii) Group 3/Ambler Class B: includes the metallo-β-lactamases that may hydrolyse carbapenems (not inhibited by clavulanic acid) and may result in resistance. They hydrolyse penicillins, cephalosporins and carbapenems but not monobactams. They are responsible for acquired resistance in several Gram-negative species. 45 (iv) Group 4: other enzymes that do not fit into the other groups. The enzyme most commonly associated with carbapenem resistance is the metalloenzyme (usually in combination with other factors as described below). The first metalloenzyme to be described was IMP-1, found in a S. marcescens isolate in Japan in 1991. 46 It has since been found in several aerobic and anaerobic Gram-negative organisms, 47 suggesting that horizontal transfer of the gene has occurred; however, it has rarely been found in isolates in the USA. To date, several different IMP genes have been detected. The VIMcarbapenemase (∼30% amino acid identity with the IMP enzymes) was first reported in Verona, Italy, in 1997 48 and, as found for IMP genes, was part of a gene cassette inserted into a class 1 integron.
Resistance in clinical isolates may be due the presence of metalloenzymes in combination with changes in permeability. An isolate of K. pneumoniae that had IMP-1 and lacked a 39 kDa porin was highly resistant to both ertapenem and imipenem (MICs > 32 mg/L); a variant that still had IMP-1 but had regained porin expression had an ertapenem MIC of 6 mg/L. 49 Similarly, Jacoby and colleagues 50 identified an ertapenem-resistant strain in which resistance was due to a combination of an AmpC β-lactamase (i.e. not a metalloenzyme) and permeability effects.
However, resistance may also be mediated by enzymes of other classes. Enzymes capable of hydrolysing carbapenems may be found in Group 1/Ambler class C, if hyperproduced and accompanied by porin changes, 44, 47 and in Groups 2 and 3 (Ambler classes A, B and D). Some Class A (clavulanic acid-inhibited) carbapenemases, while
In vitro activity of ertapenem ii19 rare, have been found in E. cloacae, and S. marcescens (chromosomal) as well as in K. pneumoniae and P. aeruginosa (plasmid encoded). Both Class A and Class B (metalloenzymes) have been implicated in acquired resistance in Gram-negative bacteria. 45 The Group 2/Class D enzymes, oxacillinases with carbapenemase properties, are found increasingly in A. baumannii. These enzymes hydrolyse imipenem and meropenem weakly and their activity is inhibited by clavulanic acid. If other carbapenem resistance determinants are present (such as permeability or efflux factors), these enzymes may contribute to carbapenem resistance.
Activity of ertapenem against isolates resistant to other antimicrobial agents
Ertapenem (and other carbapenems) are not hydrolysed (significantly) by the most common β-lactamases, and several studies have evaluated the activity of ertapenem and comparators against organisms that are resistant to other agents.
Activity against isolates with hyperproduced AmpC β-lactamase
The AmpC β-lactamases are normally chromosomal and produced at a low level. However, when these genes are found on plasmids and hyperproduced (especially when combined with changes in porins) they may cause significant resistance. They are quite rare in E. coli, probably because hyperproduction in E. coli requires a more complicated genetic change than it does in Enterobacter species. 51 When these enzymes are plasmid mediated and thus hyperproduced, they can cause broad resistance in clinical isolates of E. coli. 52 Two clinical isolates that had plasmid-mediated AmpC β-lactamases were studied; both were resistant to all cephalosporins and penicillins tested. One isolate was resistant to ertapenem (MIC 16 mg/L) but susceptible to meropenem and imipenem, although with elevated MICs. The other isolate was susceptible to all three carbapenems. More detailed studies indicated that the two isolates possessed multiple β-lactamases. 52 MICs were increased 3-fold (from 0.12 to 1 mg/L) for E. coli isolates hyperproducing AmpC. 13 Twelve isolates of an AmpC overproducer and 12 isolates with AmpC on a transmissible plasmid were susceptible to ertapenem (MIC ≤ 4 mg/L). 50 The activity of ertapenem against isolates with potent β-lactamases-both AmpC overproducers and ESBL-containing strainswas investigated. MICs for seven isolates of Klebsiella producing AmpC enzymes were ≤0.06 mg/L, although they were 2-to 4-fold higher than those for strains not hyperproducing the enzyme. Ertapenem MICs for AmpC-derepressed E. cloacae and Citrobacter freundii were much higher than the very low levels of the corresponding AmpC-basal mutants, but still below 0.5 mg/L. Studies with higher inocula did not indicate substantial lability in the presence of ESBLs or AmpC enzymes, and the authors concluded that the slightly increased MICs of ertapenem for some ESBL producers and AmpCderepressed strains may reflect other factors. 22 
Activity against isolates with broad-spectrum β-lactamases and ESBLs
The activity of ertapenem against selected strains of K. pneumoniae and E. coli producing broad-and extended-spectrum β-lactamases was investigated. 53 All the strains were susceptible to ertapenem, meropenem and imipenem. MICs of ertapenem for K. pneumoniae ranged from ≤0.03 to 0.12 mg/L and for E. coli from 0.008 to 0.12 mg/L. The activity of ertapenem was associated with excellent binding to essential penicillin-binding proteins (PBPs). In one strain tested, the binding to PBP2 was identical to that for imipenem, and the binding to PBP3 was superior to that of imipenem. Based on a limited inoculum effect on the MICs, the authors concluded that ertapenem, imipenem and meropenem may be inactivated to a small extent by broad-spectrum and extended-spectrum β-lactamases when increased amounts of the enzyme are present, but that did not cause measurable resistance (according to NCCLS criteria).
Livermore and colleagues 22 found that the ertapenem MIC 90 s for 181 isolates producing ESBLs were 0.06 mg/L, 4-to 8-fold lower than those of imipenem. Three of the isolates tested had MICs of ≥1 mg/L and one of the isolates had an MIC of 8 mg/L. In another study, MICs of ertapenem for E. coli isolates with ESBLs were much higher than MICs for strains without ESBLs, but still ≤1 mg/L (ertapenem, imipenem and meropenem MIC 90 s were 0.5, 0.5 and 0.12 mg/L, respectively 13 ). Similar results were seen for K. pneumoniae. Others tested 52 isolates that produced ESBLs (both TEM and SHV type) and found that all but one K. pneumoniae isolate (producing an SHVtype ESBL) were susceptible to ertapenem. 50 Ertapenem had MICs of <0.12 mg/L for 19 Klebsiella isolates hyperproducing the K1 β-lactamase (a Class A, Bush group 2bc enzyme 51 ); 22 the MIC 90 was 0.06 mg/L. High-level resistance to piperacillin and piperacillin-tazobactam was seen with these isolates.
Summary. Ertapenem was active against almost all isolates that had high levels of either AmpC β-lactamase, broad-spectrum β-lactamases or ESBLs. Although MICs are elevated compared with those for isolates lacking these enzymes, this does not translate into resistance to ertapenem.
Conclusion
Ertapenem is a new, broad-spectrum, Group 1 carbapenem with an extended half-life and improved stability, which has a wide spectrum of activity against community-acquired pathogens involved in a variety of infections. Unlike Group 2 carbapenems, it is not active against Pseudomonas species, A. baumannii, MRSA or enterococci. Its very potent activity against Enterobacteriaceae (including activity against strains with more potent β-lactamases) suggests utility for treating a variety of infectious diseases.
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